Clofazimine for the Treatment of Mycobacterium kansasii.

Srivastava, Shashikant; Gumbo, Tawanda

Srivastava, Shashikant; Gumbo, Tawanda.

Affiliation

Srivastava S; Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas, USA shashi.kant@bswhealth.org.
Gumbo T; Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas, USA.

Antimicrob Agents Chemother ; 62(8)2018 08.

Article in En | MEDLINE | ID: mdl-29844047

Subject(s)

Anti-Bacterial Agents/pharmacology; Clofazimine/pharmacology; Models, Biological; Models, Statistical; Mycobacterium kansasii/drug effects; Anti-Bacterial Agents/pharmacokinetics; Area Under Curve; Clofazimine/pharmacokinetics; Diffusion Chambers, Culture; Drug Administration Schedule; Drug Dosage Calculations; Ethambutol/pharmacokinetics; Ethambutol/pharmacology; Humans; Isoniazid/pharmacokinetics; Isoniazid/pharmacology; Microbial Sensitivity Tests; Mycobacterium Infections, Nontuberculous/drug therapy; Mycobacterium kansasii/growth & development; Rifampin/pharmacokinetics; Rifampin/pharmacology

Key words

benchmarking model; efflux pumps; hollow-fiber system model; pharmacokinetics/pharmacodynamics; standard therapy

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Models, Statistical / Clofazimine / Mycobacterium kansasii / Anti-Bacterial Agents / Models, Biological Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Antimicrob Agents Chemother Year: 2018 Document type: Article Affiliation country: United States Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google